AstraZeneca recently announced plans to open a new drug research and development site at the heart of Cambridge, MA, for itself and Alexion’s new corporate headquarters. The strategic center will bring together nearly 1,500 research and development, commercial, and corporate colleagu...
AstraZeneca to Build $100M Research Facility in ChinaAstraZeneca, the UK's No 2 drug maker, is to build a giant cancer research centre in China and has promised to invest $100m (pounds 54m) in research and development there over the next three years.Foley, Stephen...
AstraZenecaannouncedplans for $2 billion in new spending on research and development, bringing its total capital investment in the country to $3.5 billion by the end of 2026. The cash will be used to boost the company's research and development, as well as its manufacturing footprint in ...
he used MATLAB to develop tools that enable clinical researchers to easily apply the technology. Using MATLAB development tools and Image Processing Toolbox, Rodmell created a tool that enables research biologists to select a region in an ...
The Shanghai hub is a global strategic center that integrates research and development (R&D), commercial and production operations. It plays an important role as a strategic launching pad for AstraZeneca's global strategy, R&D and...
"We will strengthen cooperation with local partners to propel innovation and product research and development," he said. According to Yang Haiying, vice president and head of medical affairs of AstraZeneca China, the company ...
Since its entry into China in 1993, AstraZeneca has developed rapidly in the country. So far, it has invested $1.5 billion into research and development, while China has developed into AstraZeneca's second largest market. The company's production bases and logistics centers in China have export...
Drug major AstraZeneca is now looking at India and China to pursue much of their research and development initiatives. A visible trend is to source local talent as they have a better understanding of their country-specific diseases. The company also sees a fresh perspective to develop medicine ...
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally ...
The discovery, research and development of new medicines takes hundreds of scientists working together across many different disciplines. At AstraZeneca, synthetic chemistry is at the heart of this process, as chemists push into new chemical space and strive to develop ever greener manufacturing ...